Home - Chinese Journal of Cancer Research

2021 Impact Factor of CJCR: 4.026
Journal Citation Reports®, Clarivate Analytics

National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common in tumor-related mortality by Global Cancer Statistics 2020. Recent data show that the incidence and mortality of CRC in China are increasing, with the number of new cases and deaths reaching 607,900 and 261,777 in 2019. The Chinese Society of Clinical Oncology (CSCO) published the first version guidelines in April 2017 and updated annually according to the latest clinical data and the changes in China’s national conditions. Here we present the main updates of the 2022 version compared with the previous version.

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Lymphomas are a group of heterogeneous diseases, which is divided into two main categories: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). There is an estimated 75,400 incidence cases and 40,500 deaths annually in China, of which NHL accounts for about 90% of lymphoma burden.

Attributable deaths of liver cancer in China

Liver cancer is the sixth most commonly diagnosed cancer and the third cancer-related death worldwide, with 905,677 cases and 830,180 deaths in 2020. Of these, nearly 45.3% of new cases and 47.1% of deaths occurred in China. Several epidemiological studies have identified several risk factors associated with liver cancer, including chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), alcohol consumption, tobacco use, metabolic diseases such as obesity and diabetes. Of which, HBV and HCV, primary risk factors for liver cancer in China, have contributed to the most substantial proportion of liver cancer burden in China. Studies have also shown that liver cancer burden varies significantly across regions and sex due to the heterogeneous exposure of risk factors. In this study provide detailed results of the liver cancer burden in the Chinese population attributable to HBV, HCV, diabetes, excess bodyweight, alcohol drinking, tobacco smoking, and Clonorchis sinensis in 2014 stratified by age groups, sex, and provinces. HBV still contributes to the majority of liver cancer burden than any other risk factors.

‹ ›

Vol 34, No 6 (December 2022)

Review Article

Heterogeneity of tumor-infiltrating myeloid cells in era of single-cell genomics

Xiaojing Chu, Yu Zhang, Sijin Cheng

Pages: 543-553 HTML

Burden of liver cancer: From epidemiology to prevention

Qianru Li, Maomao Cao, Lin Lei, Fan Yang, He Li, Xinxin Yan, Siyi He, Shaoli Zhang, Yi Teng, Changfa Xia, Wanqing Chen

Pages: 554-566 HTML

Perspective

Postoperative functional evaluation of gastrectomy for gastric cancer

Eiji Nomura

Pages: 567-574 HTML

Advances in gastric cancer research will light the way to control this cancer

Paulo Pimentel de Assumpção, Rommel Rodrigues Burbano

Pages: 575-578 HTML

Evolution of laparoscopic gastrectomy for cancer in the East and West

Eider Talavera-Urquijo, Bas P. L. Wijnhoven

Pages: 579-586 HTML

Advances in surgical techniques for gastric cancer: Indocyanine green and near-infrared fluorescence imaging. Is it ready for prime time?

Erica Sakamoto, Adriana Vaz Safatle-Ribeiro, Ulysses Ribeiro Jr

Pages: 587-591 HTML

Original Article

Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China

Binghe Xu, Huiping Li, Zefei Jiang, Lin Gu, Jinhai Tang, Hui Xie, Yueyin Pan, Yunjiang Liu, Shude Cui, Xiaojia Wang, Li Cai, Yiqiong Zhang, Huadong Zhao, Zhimin Shao

Pages: 592-600 HTML

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera^®) in patients with CD20-positive B-cell non-Hodgkin lymphoma

Xiaohong Han, Mingzhi Zhang, Huaqing Wang, Qingyuan Zhang, Wei Li, Miaowang Hao, Yuhuan Gao, Jie Jin, Hanyun Ren, Yun Tang, Xiaonan Hong, Xiaoyan Ke, Hang Su, Lin Gui, Jianmin Luo, Liangzhi Xie, Wenlin Gai, Yuankai Shi

Pages: 601-611 HTML

Prognostic implications of tumor-infiltrating lymphocytes in association with programmed cell death ligand 1 expression in remnant gastric cancer

Marina Alessandra Pereira, Marcus Fernando Kodama Pertille Ramos, André Roncon Dias, Leonardo Cardili, Rafael Dyer Rodrigues de Moraes, Renan Ribeiro E Ribeiro, Venancio Avancini Ferreira Alves, Bruno Zilberstein, Evandro Sobroza de Mello, Ulysses Ribeiro Jr

Pages: 612-622 HTML

Clinical Practice

Chinese quality control indices for standardized diagnosis and treatment of gastric cancer (2022 edition)

Shen Li, Fei Shan, Xiaotian Zhang, Yongheng Li, Yu Sun, Lei Tang, Qi Wu, Wenjing Yang, Jincheng Yang, Yu An, Ming Deng, Jiafu Ji

Pages: 623-632 HTML

Editorial

Comments on National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

Yuan Feng, Nan Wu

Pages: 633-634 HTML

Comments on National guidelines for diagnosis and treatment of melanoma 2022 in China (English version)

Jiaran Zhang, Lu Si, Jun Guo

Pages: 635-636 HTML

Comments on National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version)

Kemin Jin, Baocai Xing

Pages: 637-643 HTML

Corrigendum

Corrigendum to Comments on National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)

Pages: 644 HTML

NHCPRC Guidelines

National guidelines for diagnosis and treatment of malignant lymphoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 425-446 HTML

National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 309-334 HTML

National guidelines for diagnosis and treatment of melanoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 335-342 HTML

National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 131-150 HTML

National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 151-175 HTML

National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 176-206 HTML

National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 207-237 HTML

National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 238-255 HTML

National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 256-269 HTML

National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 270-288 HTML

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Caixia Dong, Yuwei Ding, Shanshan Weng, Guichao Li, Yanqing Huang, Hanguang Hu, Zhen Zhang, Suzhan Zhang, Ying Yuan

Pages: 302-307 HTML

National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 415-445 HTML

Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 707-737 HTML

Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 578-585 HTML

Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 557-577 HTML

Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 223-258 HTML

Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 259-277 HTML

Chinese guidelines for diagnosis and treatment of pancreatic cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 278-294 HTML

Chinese guidelines for diagnosis and treatment of cervical cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 295-305 HTML

Chinese guidelines for diagnosis and treatment of primary lung cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 1-28 HTML

Chinese guidelines for diagnosis and treatment of renal cell carcinoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 29-48 HTML

Chinese guidelines for diagnosis and treatment of urothelial carcinoma of bladder 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 49-66 HTML

Chinese guidelines for diagnosis and treatment of prostate cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 67-83 HTML

CSCO Guidelines

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Zhijun Yuan, Shanshan Weng, Chenyang Ye, Hanguang Hu, Suzhan Zhang, Ying Yuan

Pages: 67-70 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Jun Zhu, Jun Ma, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology

Pages: 289-301 HTML

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Shanshan Weng, Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 403-407 HTML

Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018

Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 423-425 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group

Pages: 84-98 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group

Pages: 99-116 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group

2021 Impact Factor of CJCR: 4.026Journal Citation Reports®, Clarivate Analytics

National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Attributable deaths of liver cancer in China

About cjcr

Advertising

Contact us

Review Article

Perspective

Original Article

Clinical Practice

Editorial

Corrigendum

NHCPRC Guidelines

CSCO Guidelines

Virtual Special Issues

Beijing Cancer Hospital

China Anti-cancer Association

Chronic Diseases and Translational Medicine

2018 CGCC

2021 Impact Factor of CJCR: 4.026
Journal Citation Reports®, Clarivate Analytics